The online version of this article (doi:10.1186/1477-7819-10-232) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
Xi JJ collected information of the cases, carried out statistic analysis, conducted follow-ups, and drafted the manuscript. Jiang W collected information of the cases and participated in the revision of the manuscript. Lu SH verified the diagnosis and performed immunohistochemistry. Zhang CY carried out the detection of gene mutation. Fan H participated in collecting information of cases and manuscript drafting. Wang Q conceived the article and participated in the manuscript drafting. All authors read and approved the final manuscript.
The optimal treatment for pulmonary mucoepidermoid carcinoma (MEC), a rare type of tumor, has not been established yet. This study analyzed the survival of pulmonary MEC patients and attempted to find clues for optimal treatment.
A total of 21 patients with pulmonary MEC from November 2004 to January 2011 were included in the investigation. Immunohistochemistry, epidermal growth factor receptor (EGFR) mutation, and survival were retrospectively studied.
Among the 21 pulmonary MEC patients, 17 were diagnosed with low-grade malignancy and 4 with high-grade malignancy through pathological examination. The prognosis was found to be poor in the presence of lymph nodes. The expression rates of EGFR and HER2 were 28.6% and 0%, respectively, which correlated with neither grade nor prognosis. The mutation rate of EGFR was 0. Log-rank test results indicated that age, grade, lymph node metastasis, and tumor-node-metastasis stage were prognostic factors.
Age, grade, lymph node metastasis and tumor-node-metastasis stage correlate with the survival of pulmonary MEC patients.
This study was approved and registered by the Ethics Committee of Zhongshan Hospital. Written informed consent was obtained from all participants prior to treatment.
Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001, 92: 1331-1346. 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M. CrossRefPubMed
Smetana HF, Iverson L, Swan LL: Bronchogenic carcinoma; an analysis of 100 autopsy cases. Mil Surg. 1952, 111: 335-351. PubMed
Roggenbuck C, Hau T, de Wall N, Buss H: Simultaneous occurrence of tracheobronchopathia osteochondropastica and mucoepidermoid carcinoma. Chirurg. 1995, 66: 231-234. PubMed
Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC: Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol. 2008, 21: 1168-1175. 10.1038/modpathol.2008.113. PubMedCentralCrossRefPubMed
- Primary pulmonary mucoepidermoid carcinoma: an analysis of 21 cases
- BioMed Central
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II